Round-up of developments in biopharm contract services
O2h providing chemistry and ADME services to Phytopharm
O2h is providing chemistry and ADME services to support drug discovery programmes at Phytopharm.
UK-based Phytopharm is developing a series of compounds, the Sapogenins, for treating neurodegenerative diseases such as Parkinson’s, motor neurone and glaucoma.
"I have known O2h for a number of years and am aware of their extensive experience of providing chemistry and ADME support to virtual companies around the world”, said Tim Sharpington, CEO of Phytopharm.
O2h is co-located in Cambridge, UK and Ahmedabad, India. The UK office provides project management support while the Indian operations offer expertise in chemistry, including adsorption, distribution, metabolism, and excretion (ADME).
Biomoda selects RCRI
RCRI is to support the upcoming Biomoda clinical trial of the CyPath diagnostic for early detection of lung cancer. CyPath binds to cancer cells and fluoresces under specific frequencies of medium light.
John Cousins, president of Biomoda, said: “RCRI’s strategic approach to clinical trial design and management will provide additional expertise to the pivotal trial.” RCRI is the “perfect partner” to help Biomoda through the increasingly complex clinical trial process, said Cousins.
Texcell partners to enter US
France-based Texcell has partnered with Cell Trends, a Maryland-based contract research organisation (CRO), to increase its presence in North America.
“The partnership with Cell Trends provides a strong opportunity to develop new business relationships with biotech and pharmaceutical companies on both sides of the Atlantic Ocean", said Bernard Plichon, President and CEO of Texcell.
